3，5-dimethyl-Tricyclo[3.3.1.13,7]decan-1-amine

The main ingredient of this product is memantine hydrochloride. Chemical name: 1-amino-3,5-dimethyladamantaneamine hydrochloride, molecular formula: C12H21N·HCl, molecular weight: 215.77

1: When NMDA antagonists are used in combination, the effects of levodopa, dopamine receptor agonists, and anticholinergic drugs may be enhanced, and the effects of barbiturates and neuroleptics may be weakened. When memantine is used in combination with anticonvulsants (such as dantrolene or baclofen), the effects of these drugs may be altered, so dose adjustment is required. 2: Because memantine and amantadine are both NMDA antagonists in chemical structure, their combination should be avoided to avoid drug-induced psychosis. For the same reason, memantine should not be used in combination with ketamine or dextromethorphan. In a published report, the risk of co-administration of memantine and phenytoin may be increased. 3: Because other drugs (such as cimetidine, ranitidine, procainamide, quinidine, quinine, and nicotine) share the same renal cation transport system as amantadine, they may also interact with memantine, leading to the potential risk of increased plasma levels. 4: When memantine is used in combination with hydrochlorothiazide or any combination preparation containing hydrochlorothiazide, the serum level of hydrochlorothiazide may be reduced. 5: Memantine does not inhibit the activity of cytochrome enzymes (CYP1A2, 2A6, 2C9, 2D6, 2E1, 3A), epoxide hydrolases and sulfation and monooxygenase-containing flavins under in vitro conditions.

The main ingredient of this product is memantine hydrochloride.

According to the pharmacological effects and mechanisms of action of this product, the following interactions may occur: ● When NMDA antagonists are used in combination, the effects of levodopa, dopamine receptor agonists, and anticholinergic drugs may be enhanced, and the effects of barbiturates and neuroleptics may be weakened. When memantine is used in combination with anticonvulsant drugs (such as dantrolene or baclofen), the effects of these drugs may be altered, so dose adjustment is required. ● Because memantine and amantadine are both NMDA antagonists in chemical structure, their combined use should be avoided to avoid drug-induced psychosis. For the same reason, memantine should not be used in combination with ketamine or dextromethorphan. In a published report, the risk of combined use of memantine and phenytoin may increase. ● Because other drugs (such as cimetidine, ranitidine,

The main ingredient of this product is memantine hydrochloride. Chemical name: 1-amino-3,5-dimethyladamantaneamine hydrochloride, molecular formula: C12H21N·HCl, molecular weight: 215.77

1: When NMDA antagonists are used in combination, the effects of levodopa, dopamine receptor agonists, and anticholinergic drugs may be enhanced, and the effects of barbiturates and neuroleptics may be weakened. When memantine is used in combination with anticonvulsants (such as dantrolene or baclofen), the effects of these drugs may be altered, so dose adjustment is required. 2: Because memantine and amantadine are both NMDA antagonists in chemical structure, their combination should be avoided to avoid drug-induced psychosis. For the same reason, memantine should not be used in combination with ketamine or dextromethorphan. In a published report, the risk of co-administration of memantine and phenytoin may be increased. 3: Because other drugs (such as cimetidine, ranitidine, procainamide, quinidine, quinine, and nicotine) share the same renal cation transport system as amantadine, they may also interact with memantine, leading to the potential risk of increased plasma levels. 4: When memantine is used in combination with hydrochlorothiazide or any combination preparation containing hydrochlorothiazide, the serum level of hydrochlorothiazide may be reduced. 5: Memantine does not inhibit the activity of cytochrome enzymes (CYP1A2, 2A6, 2C9, 2D6, 2E1, 3A), epoxide hydrolases and sulfation and monooxygenase-containing flavins under in vitro conditions.